<DOC>
	<DOCNO>NCT00090051</DOCNO>
	<brief_summary>The purpose study provide treatment patient chronic lymphocytic leukemia ( CLL ) , compare use rituximab add fludarabine+cyclophosphamide ( FC ) FC alone , determine rituximab lengthen time patient remain free leukemia symptom .</brief_summary>
	<brief_title>FCR Versus FC Alone Treatment Chronic Lymphocytic Leukemia ( CLL ) Relapsed Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Age ≥18 year Established diagnosis Bcell CLL NCI Working Group criteria ≤1 previous line chemotherapy Expected survival &gt; 6 month Acceptable hematologic status , liver function , renal function , pulmonary function Negative serum pregnancy test premenopausal woman woman &lt; 2 year onset menopause Written inform consent Prior treatment interferon , rituximab monoclonal antibody Prior allogeneic bone marrow transplant ( BMT ) autologous BMT peripheral stem cell transplant ( PBSCT ) patient consider candidate allogeneic autologous BMT PSCT assess treat physician Fertile men woman childbearing potential use adequate contraception Severe Grade 3 4 nonhematological toxicity prolong ( &gt; 2 week ) Grade 3 4 cytopenia prior fludarabine nucleoside analogue regimen History fludarabineinduced clinically significant autoimmune cytopenia History malignancy within 2 year prior study entry , except adequately treat carcinoma situ cervix ; basal squamous cell skin cancer ; lowgrade early stage localize prostate cancer treat surgically curative intent ; good prognosis ductal carcinoma situ ( DCIS ) breast treated lumpectomy alone curative intent . Medical condition require long term use ( &gt; 1 month ) systemic corticosteroid Active bacterial , viral , fungal infection require systemic therapy Severe cardiac disease Seizure disorder require anticonvulsant therapy Severe chronic obstructive pulmonary disease hypoxemia Uncontrolled diabetes mellitus hypertension Transformation aggressive Bcell malignancy . Known infection HIV , HCV , hepatitis B Treatment investigational agent , participation another clinical trial within 30 day prior enter study Known hypersensitivity anaphylactic reaction murine antibody proteins Any coexist medical psychological condition would preclude participation study compromise ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>